The study is a perfect mix of qualitative and quantitative information highlighting key market developments, challenges that industry and competition are facing along with gap analysis and new opportunity available and trend in Cutaneous Leishmaniasis Drugs.
Seattle, WA -- (SBWIRE) -- 12/05/2019 -- What is Cutaneous Leishmaniasis Drugs?
Cutaneous Leishmaniasis is a parasitic disease. It is spread by the female sand-fly, which occurs in the new world and the old world. The drugs approved for cutaneous leishmaniasis treatment include fluconazole, tablet azole antifungals-systemic, Diflucan, Diflucan tablet azole antifungals-systemic, impavido, miltefosine capsule, pentam 300 solution, reconstituted, off and pentamidine 300 mg solution for injection antiprotozoal agents are.
Apply Here for Free PDF Brochure: https://www.worldwidemarketreports.com/sample/286276
Global Cutaneous Leishmaniasis Drugs Market Outlook
About 95% of cutaneous leishmaniasis cases occur in the Americas, the Mediterranean Basin, the Middle East, and Central Asia. In 2017 over 95% of new cutaneous leishmaniasis cases occurred in six countries: Brazil, Colombia, Afghanistan, Algeria, Iran, Iraq, and the Syrian Arab Republic. According to the World Health Organisation, it is anticipated that between 600 000 to 1 million new cases arise worldwide yearly.
Cutaneous leishmaniasis cases have increased intensely in Syria and neighbouring countries due to the conflict-related displacement of Syrians. Advancement in drug therapies to provide a new treatment for cutaneous leishmaniasis. The current strategy is to control this disease mainly based on chemotherapy, presently used therapies against cutaneous leishmaniasis lead to complete cure. However, they associate with many limitations, efficacy remains hindered by the patient's age and immune system.
Lack of awareness, high cost of treatment and prolong treatment span hinders the growth of the market. World Health Organisation (WHO) considers leishmaniasis to be one of the main neglected diseases in the world, affecting mostly the poor population of underdeveloped and developing countries.
Global Cutaneous Leishmaniasis Drugs Market Competitive Landscape
The "Global Cutaneous Leishmaniasis Drugs Market" study report will provide a valuable insight with an emphasis on global market including some of the major players such as GlaxoSmithKline, Novartis, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Albert David, Profounda, Knight Therapeutics and Johnson & Johnson. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis.
Place an Inquire for Full ToC: https://www.worldwidemarketreports.com/quiry/286276
Customisation of the Report
In case of any queries or customisation requirements please connect with our sales team, who will ensure that your requirements are met.